Skip to content

A Twenty-years' Experience in Pituitary Disease.

A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06973824
Acronym
TYEPDD
Enrollment
1600
Registered
2025-05-15
Start date
2025-03-10
Completion date
2028-04-30
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Adenoma, Pituitary Cancer, Pituitary Disease

Brief summary

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Interventions

OTHERFrequency of disease recurrence

To collect data of pituitary disease recurrence

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients underwent surgery for pituitary tumors; * pathology diagnosis of pituitary tumors; * patients older then 18 years at diagnosis of pituitary tumors; * 2 years follow-up;

Exclusion criteria

* age lower then 18 years * follow-up shorter than 2 years

Design outcomes

Primary

MeasureTime frameDescription
Tumor recurrenceFrom enrollement to last observation at 24 months of follow-upFrequency of tumor recurrence at 24 months of follow-up

Countries

Italy

Contacts

Primary ContactFrancesco Doglietto, Prof
francesco.doglietto@policlinicogemelli.it+390630155701
Backup ContactSabrina Chiloiro, MD
sabrina.chiloiro@policlinicogemelli.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026